Vincent Liptak, J.D., Ph.D., MBA is executive vice president and general counsel at BlossomHill Therapeutics. Dr. Liptak has more than 20 years of experience in the legal profession. Prior to joining BlossomHill, he was a partner at Barnes & Thornburg, LLP, serving as outside counsel for many chemical and life sciences clients. While at Barnes & Thornburg, Dr. Liptak was co-chair of the firm’s Life Sciences Practice Group. With pharmaceutical patents as his practice focus, he has written hundreds of patents covering many aspects of pharmaceutical compounds, including patents covering several FDA-approved products. He has worked with BlossomHill’s Scientific Founder, President, and CEO Dr. J. Jean Cui, for nearly 20 years, beginning as colleagues at Pfizer, Inc. in La Jolla, Calif. Throughout his career, Dr. Liptak has written patents that cover crizotinib (XALKORI®), lorlatinib (LORBRENA®), repotrectinib (AUGTYRO®) and elzovantinib, as well as other compounds discovered by Dr. Cui and her colleagues at Pfizer, Turning Point Therapeutics, Inc. and BlossomHill.
He received his Master of Science and doctorate from The University of Chicago, a J.D. and Master of Business Administration from the University of San Diego and a Bachelor of Science with a double major in chemistry and mathematics from Loyola University Chicago. Before entering the legal profession, Dr. Liptak was a postdoc in Prof. Dennis Dougherty’s laboratory at the California Institute of Technology in Pasadena, Calif. He is registered to practice law in California and Indiana and is registered to practice before the United States Patent and Trademark Office.
What is Vincent Paul Liptak's net worth?
The estimated net worth of Vincent Paul Liptak is at least $1.78 million as of August 10th, 2026. Dr. Liptak owns 111,412 shares of BlossomHill Therapeutics stock worth more than $1,775,907 as of August 21st. This net worth estimate does not reflect any other assets that Dr. Liptak may own. Learn More about Vincent Paul Liptak's net worth.
How do I contact Vincent Paul Liptak?
Has Vincent Paul Liptak been buying or selling shares of BlossomHill Therapeutics?
During the last ninety days, Vincent Paul Liptak has bought $74,700.00 of BlossomHill Therapeutics stock. Most recently, on Monday, August 10th, Vincent Paul Liptak bought 2,200 shares of BlossomHill Therapeutics stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $35,200.00. Following the completion of the transaction, the general counsel now directly owns 111,412 shares of the company's stock, valued at $1,782,592. Learn More on Vincent Paul Liptak's trading history.
Who are BlossomHill Therapeutics' active insiders?
Are insiders buying or selling shares of BlossomHill Therapeutics?
In the last year, BlossomHill Therapeutics insiders bought shares 7 times. They purchased a total of 1,573,900 shares worth more than $25,181,900.00. The most recent insider tranaction occured on August, 10th when Director John P Schmid bought 6,000 shares worth more than $96,000.00.
Learn More about insider trades at BlossomHill Therapeutics. Information on this page was last updated on 8/10/2026.
